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replaces DM20 measuring percentage of patients with HbA1c less than 7; DM24 (new 
indicator) measuring percentage with HbA1c less than 8; DM25 replaces DM07 mea-
suring percentage with HbA1c less than 9. The analysis objective is to estimate likely 
achievement of these new indicators and assess impact on QOF points. METHODS: 
Underlying achievement of current clinical indicators, reported by NHS Information 
Centre, is 66.8% and 92.3%, with average points achievement of 98.3% (16.7 from 
17) and 97.9% (10.8 from 11) for DM20 and DM07 respectively. Mean HbA1c of 
6.9 (standard deviation 1.5; 1–2 years after entry to study) was taken from UKPDS 
56. 252 HbA1c values (average diabetes QOF register) were generated from this dis-
tribution and percentage achievement of current and proposed indicators was calcu-
lated. This simulation was repeated 8,294 times (number of QOF practices) and 
average achievement for each indicator was noted. RESULTS: Average achievement 
of current indicators using UKPDS 56 distribution was estimated at 65.5% and 98.1% 
for DM20 and DM07 respectively, comparing favourably with reported results. 
Average achievement of proposed QOF indicators was estimated at 52.7%, 76.8% 
and 91.9% with maximum points (35 in total) awarded at 50%, 70% and 90% for 
DM23, DM24 and DM25 respectively. CONCLUSIONS: Although the QOF targets 
for HbA1c are lower, the average percentage achievement is estimated to reach the 
level required for maximum QOF points. However, since the average is close to the 
maximum payment level for DM23 and DM25 a number of practices are unlikely to 
reach this unless increased reductions in HbA1c are achieved.
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OBJECTIVES: Understanding current and new paths of treatment (POT) in diabetes 
is pivotal for estimating budget impacts when new antidiabetic agents are introduced 
to pharmacy formularies. Although diabetes treatment guidelines exist to guide pre-
scribers, very limited real-life data are available to illuminate actual POT’s for patients 
initiating insulin treatment. The aim of this study was to establish the most prevalent 
POT’s for insulin initiation using real-world US pharmacy data. METHODS: Medic-
aid, Cash and 3rd party payer pharmacy claims were obtained from SDI. A patient’s 
ﬁrst insulin Rx between October and December. 2004 served as an index Rx. A 6 
month look-back identiﬁed prior treatments and a 3 year look-forward tracked 
changes from the index Rx. To be eligible for analysis, patients had to have no insulin 
Rx in the look-back and be in the SDI database in the ﬁrst and last quarter of observa-
tion. The pattern of payers and prescribers were identiﬁed along with the most fre-
quent Rx combinations for each step. The average duration for each step was analyzed. 
RESULTS: Out of 351,887 patients with an index insulin Rx, 78,213 had no insulin 
in the look-back. Claims were paid by Medicaid (13%), cash (4%), and 3rd party 
(83%). The top-10 combinations prior to the index insulin constituted 96% of the 
data. The top 3 were Metformin(MET)  Sulfonylurea(SU) (18%), Met alone (17%) 
and SU alone (13%). The top-10 combinations initiating index insulin constituted 
59% of the data. The top 3 were MET  SU  basal insulin (11%), MET  SU  TZD 
 basal insulin (11%), and SU  basal insulin (6%). On average, patients initiating 
insulin went 230 days without changing their therapy. CONCLUSIONS: Based on 
real-world US data, a small number of therapy combinations explain the POT’s before 
insulin initiation. Upon initiating insulin treatment, combinations are more varied, 
although most include basal insulin.
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OBJECTIVES: Enfuvirtide is part of a novel class of agents known as fusion inhibitors 
approved following the phase III TORO trials. The objective of ZOOM cohort was 
to assess in real life setting long term efﬁcacy and safety of enfuvirtide in HIV-1 
patients. METHODS: ZOOM is a multicenter, observational, longitudinal, prospec-
tive French study conducted from September 2004 to September 2006. The main 
objectives were immuno-virological and clinical assessments during the treatment and 
after a 2 year follow-up. Secondary objectives were patient’s characteristics, drug 
treatment modalities, safety and quality of life. RESULTS: During this period, 364 
patients were included, their characteristics were as follow: mean age : 45 o 9 years, 
median viral load: 4,70 log10 copies/ml, median CD4 count : 155 cell/mm3; AIDS 
deﬁning events : 52%; antiretroviral pre-treated patients: 97% since a mean of 10 o 
3 years. These characteristics were similar to the HIV French Hospital database. At 
24 months, 43% of treated patients had an undetectable HIV plasma viral load 
(threshold 400 copies/mL) and 39% had a CD4 increase of at least 100 cell/ mm3 
(versus 27% and 32% respectively in the TORO trial). The most common adverse 
event was injection site reaction (93% versus 98% in TORO). In addition, the prob-
ability at 12 months of an AIDS deﬁning events or patient death was 12% (IC95% 
 [9%; 16%]). CONCLUSIONS: The ZOOM observational study conﬁrmed, in real 
life setting, enfuvirtide safety and efﬁcacy demonstrated in the TORO trials. It also 
shows that enfuvirtide drug treatment modalities follow the summary of product 
characteristics recommendations.
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OBJECTIVES: Hepatic impairment from chronic hepatitis C (CHC) has signiﬁcant 
implications for drugs that are extensively cleared by liver, presenting extra challenges 
to manage comorbidities for CHC patients. This study is to assess the comorbidity 
burden of hepatitis C virus (HCV) infection in Europe to better understand the needs 
for proper disease management of patients with CHC. METHODS: National Health 
and Wellness Survey (NHWS) is an annual cross-sectional survey from representative 
adults, including information regarding health care attitudes, behaviors, demographic 
and disease characteristics, resource utilization, and health-related outcomes. In this 
study, NHWS data obtained from France, Germany, Italy, Spain, and UK in 2006–
2008 were analyzed and self-reported CHC were categorized as cases. Propensity-
matched non-CHC survey responders were selected as controls based on country, 
gender, age, education, employment, and year of survey. Conditional logistic regres-
sion was applied controlling for HIV, marital status, smoking status, alcohol consump-
tion and body mass index. RESULTS: The ﬁnal sample included 864 cases and 864 
closely matched controls: 61% were male with mean age of 49.8. After adjusting for 
HIV status, the most prevalent conditions ever experienced by CHC patients included 
hypertension (27%), high cholesterol (17%), diabetes (12%), chronic bronchitis 
(11%), arthritis (10%), hepatitis B (10%), thyroid disorders (10%), cancer (9%), and 
ulcer (gastric or duodenal—9%). Compared to the control adjusting for HIV status 
and other covariates, CHC patients were associated with signiﬁcantly higher risks for 
32 medical conditions collected in the survey. CONCLUSIONS: CHC patients have 
a high burden of comorbidities, many of which require long-term or intensive phar-
macological management. This could suggest that treating HCV infection early to 
prevent the deterioration in liver function is essential for the management of comorbid 
conditions, and should be among the key goals of comprehensive CHC management 
strategies.
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OBJECTIVES: LPV/r SAT may durably suppress HIV and maintain immunologic 
response in multiple trial settings, but criteria for improved clinical outcomes have 
not been determined. Our objective was to evaluate LPV/r SAT use and predictors of 
viral suppression in an urban clinic setting. METHODS: A retrospective, longitudinal 
cohort study was conducted of all patients q18 years old with q2 HIV-1 RNA (“viral 
load”, VL) measurements starting LPV/r SAT from 2003–2007 at a large urban HIV 
clinic. Exclusion criteria: prospective clinical trial enrollment or missing data. Vari-
ables (demographics, baseline plasma VL and CD4, previous HAART, adherence, and 
missed clinic visits) evaluated by univariate and stepwise logistic regression to deter-
mine predictors of virologic suppression (achievement and/or maintenance of VL  
50copies/mL). RESULTS: Ninety-one patients met inclusion criteria (73% male; 54% 
black, 35% Caucasian, and 11% Hispanic). Mean age was 42.4 years, median CD4 
prior to SAT 290 cells/mm3, and median VL 8960 copies/mL. Reasons for SAT (pro-
vider and patient perspective): easy regimen (29%), simpliﬁcation/maintenance (26%), 
antiretroviral toxicity (21%), and adherence (23%). In patients with q6 months 
follow-up (n  82), 37 were HAART-naïve and 45 had q1 previous HAART regimen. 
Overall, 73% of HAART-naïve and 47% of patients with q1 previous HAART 
regimen achieved/maintained viral suppression. In univariate analyses, age, adherence, 
ethnicity, low VL, high CD4, and AIDS status were signiﬁcant predictors (p  0.05). 
Regression analysis indicated age  50 years (OR 5.2 [95% CI, 1.1–18.4]), white 
ethnicity (OR 2.5 [1.1–8.3]), and no AIDS (OR 3.0 [1.2–12.5]) were independently 
associated with viral suppression (p  0.05). SAT was stopped in 17/91 patients for 
viral failure, poor adherence, drug toxicity, or drug cost. CONCLUSIONS: Incidence 
of viral suppression was similar to prospective controlled trials in HAART-naive 
patients. Older patients with no/mild immunosuppression and limited prior antiretro-
viral experience may be better candidates for LPV/r SAT. Larger, prospective evalua-
tions are needed.
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OBJECTIVES: The main goal of the review was to compare clinical effectiveness 
of imiquimod 5% cream versus vehicle or conventional ablative methods for the 
